Key facts
- Notable investors include Imbolc Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Jeevan Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Jeevan Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Jeevan Therapeutics
Operator of a biotechnology firm intended to offer medicines for treating immune disorders and cancers. The company offers a platform to target signaling pathways that control cell functions like proliferation, differentiation and tissue homeostasis and addresses immune aging-related vulnerabilities in immunotherapies, enabling healthcare professionals to take care of patients.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2024
- Employees
- 3
- Website
- jeevantx.com/
- Ownership
- Privately Held (backing)
Jeevan Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Jeevan Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Jeevan Therapeutics in its N-PORT filings yet. We sweep new filings monthly.